Development and validation of a nomogram incorporating axillary lymph node ratio to predict survival in node-positive breast cancer patients after neoadjuvant chemotherapy 
Introduction
Breast cancer (BC) is an enormous public health problem in China and the crucial cause of female cancer death, accounting for nearly 15% of all new cases in women (1) . Neoadjuvant chemotherapy (NACT) is increasingly used to convert inoperable to operable disease and can facilitate breast-conserving surgery (2) (3) (4) (5) . Nevertheless, the prognosis for patients with locally advanced tumors after NACT remains poor, especially in node-positive BC patients. The number of involved axillary lymph nodes (ALNs) is a significant prognostic indicators of survival in BC patients (6) . Besides, it was reported that the number of dissected ALNs also influenced the accuracy of prognosis in BC patients (7) . However, in the traditional American Joint Committee on Cancer (AJCC) TNM classification for BC, the ypN staging is merely on the basis of the number of involved ALNs and has been criticized for ignoring the influence of the number of removed ALNs on survival. Hence, more appropriate methods for accurate estimation of the ALN status in BC patients after NACT are imperative.
Over the past decade, to address this issue, several authors have suggested that axillary lymph node ratio (ALNR), defined as the ratio of the number of involved ALNs to the number of removed ALNs, is a superior prognostic factor for survival than the current AJCC ypN staging in the NACT setting (8) (9) (10) (11) . Compared with the AJCC ypN staging, in conjunction with the number of excised ALNs, the ALNR may be a more comprehensive indicator for survival. Axelsson et al. reviewed a number of 13 851 BC patients and found a significantly poor prognosis when less than 10 ALNs were removed at axillary dissection (12) . However, it should be noted that, when compared with BC patients in the non-NACT setting, more patients who received NACT had less than 10 ALNs dissected, which may lead to underestimation of the ALN status and thus affects risk prediction of survival (10, (13) (14) (15) (16) . Consequently, the ALNR may be a more appropriate method in the pathological assessment of the ALN status after NACT. However, few studies have incorporated the prognostic value of ALNR to provide accurate individualized estimates of survival in node-positive BC patients after NACT.
Therefore, in the present study, we sought to establish ALNRbased nomogram to accurately predict disease-free survival (DFS) and risk stratification in node-positive BC patients after NACT.
Materials and methods

Participants and study design
We performed a retrospective review of 339 node-positive BC patients who underwent NACT at the Sun Yat-sen Memorial Hospital (SYSMH, derivation group) from August 2002 to December 2014 and the First People's Hospital of Foshan (FPHF, validation group) from January 2009 to December 2012. The inclusion criteria were included: (i) histologically confirmed primary BC before NACT; (ii) treated with NACT regimens before surgery; (iii) underwent ALN dissection after NACT; (iv) patients with positive ALNs after ALN dissection. Patients with negative ALNs after ALN dissection and metastatic disease before surgery were not eligible in the study. The present study was approved by the Institutional Ethics Committees of the SYSMH and FPHF. And the informed consent was waived in the retrospective study.
NACT regimens, follow-up and clinical outcome
The NACT regimens were demonstrated in a previous study (17) . Follow-up was conducted at a period of 3 months for the first 2 years after surgery, at a period of 6 months for the 2-5 years since surgery and at a period of 1 year thereafter. Physical examinations were routinely carried out at each follow-up visit, including blood test, breast ultrasonography (US), abdominal US, chest X-ray and gynecological US. Mammography and MRI were required at a period of 1-2 years. The primary endpoint was DFS, determined as the interval between the date of surgery and the date of relapse (local/ regional relapse or distant metastasis), second primary tumor, death or the last follow-up (18) .
Statistical analysis
Descriptive analysis was performed for clinicopathological features of included patients. Univariate and multivariate analyses were implemented using Cox proportional hazards regression (CPHR). Survival curves were calculated via the Kaplan-Meier method and compared via the log-rank test. The C-index, calibration curve, risk group stratification and decision curve analysis (DCA) were used to assess the discrimination, calibration ability and clinical usefulness of the ALNR-based model, respectively. The optimal cut-off values were identified via X-tile software, version 3.6.1 (Yale University, New Haven, CT, USA) (19) . Stata/MP, version 14.0 (StataCorp LP, College Station, TX) and R version 3.4.4 were used to the statistical analyses. The related R packages were applied in construction and assessment of the nomogram, including 'rms', 'glmnet', 'Hmisc', 'survival', 'generalhoslem', 'ggplot2' and'Dca.R'. A P value was determined significant (P < 0.05).
Results
Patient characteristics
Data from 339 node-positive BC patients who underwent NACT and ALN dissection at the SYSMH (n = 271, derivation set) and the FPHF (n = 68, external validation set) were respectively collected. Table 1 
Independent prognostic factors for DFS in the derivation set
As shown in Table 2 , according to univariate and multivariate CPHR analyses, eight variables were confirmed as independent predictors for DFS (P < 0.05), including age, pathological T stage, ALNR, histological grade, ER, Ki67, lymphovascular invasion and adjuvant hormonal therapy (HT). Adjuvant HT was correlated with ER status, known as multicollinearity, could affect the beta coefficients in the nomogram, resulting in spurious associations and unreliable statistical results (20) . Thus, adjuvant HT was not included into the model. Finally, we incorporated the seven independent factors to build the ALNR-based nomogram (Fig. 1) .
Performance of the ALNR-based nomogram
The C-indices of the ALNR-based model were 0.773 (95% CI: 0.734-0.813) and 0.816 (95%: 0.748-0.883) in the derivation group and the external validation group, respectively. Calibration curves illustrated optimal agreement between model predicted and actual observations (Fig. 2) . With respect to the discrimination ability, the ALNR-based nomogram was higher than that of the eighth edition AJCC TNM classification in the SYSMH cohort (0.773 vs 0.610). Furthermore, we also calculated the C-index of the N stagebased nomogram (0.759). Obviously, the C-index of the ALNR-based nomogram was higher than that of the N stage-based nomogram (0.773 vs 0.759). Therefore, the predictive performance of the ALNRbased nomogram was superior to the N stage-based nomogram. Moreover, in terms of the clinical utility, DCA demonstrated that the ALNR-based nomogram was superior to the current AJCC TNM staging system across the wider range of reasonable threshold probabilities ( Fig. 3) (21-26) .
Risk stratification on the basis of the ALNR-based nomogram
As shown in Table 3 , prognostic scores of all independent variables were assigned on the basis of the established nomogram. According to the total points (from lowest to highest) in the SYSMH cohort, we used X-tile software to identify the optimal cut-off values (19) . Subsequently, all the patients were classified into two groups: lowrisk (≤19.8) and high-risk (>19.8) groups, corresponding to 5-year DFS rates of 77.6 and 15.4%. Additionally, as illustrated in Fig. 4 , based on effective risk group stratification, Kaplan-Meier curves for DFS were conducted in the derivation group and the external validation group, respectively (all P < 0.0001). Obviously, the low-risk patients had significantly better DFS than the high-risk patients (P < 0.0001, Fig. 4) .
Discussion
In the present study, the proposed ALNR-based nomogram, which included seven comprehensive prognostic predictors, had high discrimination, calibration ability and robust clinical usefulness. To our knowledge, this is the first study in which a nomogram incorporating the prognostic value of ALNR is established to improve individualized prediction of survival and make effective risk stratification in node-positive BC patients after NACT. Others, TC (docetaxel, and cyclophosphamide); TCH (docetaxel, carboplatin, and trastuzumab). DFS, disease-free survival; HR, hazard ratio. Currently, the number of positive ALNs is included into the traditional AJCC ypN staging system, which cannot take into account of the total number of dissected ALNs. On the one hand, it is widely considered that 10 ALNs are imperative for accurate evaluation and staging in BC patients with ALN dissection (27) . However, NACT may modify the number of ALNs and a lower ALNs count was often found in the NACT setting, which may lead to underestimate the prognostic value of ALN status (10, 13) . One of the possible reasons was that fibrotic involution resulted in a barrier to the pathological assessment of specimens. On the other hand, the number of involved ALNs increases with the number of dissected ALNs, and potential involved ALNs will be cleared out with a more extensive ALN dissection, which depends on the surgeon's experience (28) (29) (30) . To resolve this dilemma, several authors have advocated that the ALNR may be considered as a complementary or an alternative to the AJCC ypN staging (8, 10, 11, 31) . Nevertheless, few study has developed a practical tool integrating the ALNR to accurately predict survival in node-positive BC patients after NACT. To determine generalizability of the ALNRbased nomogram, it is essential to validate the prognostic model.
The C-index of the ALNR-based model was superior to that of the AJCC TNM classification (0.773 vs 0.610), which indicated that our nomogram had better predictive accuracy. Meanwhile, compared with the AJCC TNM staging system, the ALNR-based nomogram had wider range of threshold probabilities on DCA, which showed that our nomogram had better clinical utility. Hence, the ALNR-based nomogram enable to provide individualized estimates of survival more accurately in node-positive BC patients after NACT.
To date, there is distinct heterogeneity in BC patients who are stratified based on the traditional AJCC TNM classification. Because BC patients with equivalent anatomical spread yet different survival outcomes are in the same stage, disregarding the heterogeneity of BC (32) . To address the heterogeneity, the ALNR-based nomogram was developed to make better risk stratification in nodepositive BC patients after NACT. Therefore, it can be used to assist oncologists in selecting the proper patients to receive more appropriate post-operative adjuvant treatment. For example, adjuvant therapy may be reasonably tailored to avoid overtreatment in the low-risk patients, especially in the older patients. By contrast, the high-risk patients should be receive more intensive post-operative adjuvant treatment and follow-up, especially in the younger patients. In addition, the ALNRbased nomogram also can be applied to classify BC patients in designing clinical trials on the basis of the accurate prognostic stratification. Moreover, this tool may facilitate the communication between clinicians and patients.
Some potential limitations in the current study should be acknowledged. First, this was a retrospective study with limited cases, thus selection bias may exist. And surgical and pathological bias may affect the number of nodes retrieved at axillary dissection. Second, our study was conducted only in the Asian populations, thus the generalizability of the nomogram still need to be validated in the western populations. Third, molecular biomarkers should be taken into account to enhance the predictive accuracy of the nomogram in further research. Fourth, there was difference between the derivation cohort and the external validation cohort, which might be due to the limited sample size of validation cohort. Thus, the nomogram should be prospectively validated with a larger, independent data set in further research.
In conclusion, the ALNR-based nomogram was constructed and externally validated to predict survival in node-positive BC patients after NACT. This practical tool has better predictive accuracy and clinical usefulness than that of the conventional AJCC TNM staging system. The user-friendly model can be used to improve individualized risk prediction of survival in node-positive BC patients after NACT and assist oncologists in selecting the high-risk patients who are in the need of a specific treatment strategy.
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